Bristol-Myers Squibb (BMY)

The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have commanded significant attention with their pronounced stock swings. As of November 18, 2025, both companies find themselves at pivotal junctures, with

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Exchange-traded funds provide investors with exposure to a basket of stocks. Some also pay dividends.

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.

Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Investors stepped back into beaten-down tech names Friday, with the Nasdaq 100 rising 0.6% by midday in New York, staging a modest rebound after Thursday's sharp selloff.

Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and stroke studies continue with data expected in 2026.

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.

An independent data monitoring committee said the company's treatment for acute coronary syndrome was likely to fail in testing.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.

The decision follows an analysis by an independent data monitoring committee that the trial is unlikely to meet its key goal.

While the S&P 500 is up 16.3% since May 2025, Bristol-Myers Squibb (currently trading at $48.73 per share) has lagged behind, posting a return of 10.4%. This might have investors contemplating their next move.

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Turn health into wealth with these three high-yielding dividend stocks.

"Mad Money" host Jim Cramer discusses Bristol-Myers Squibb, Baidu, Alibaba, Brinker and New Era Energy & Digital.

San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results from its pivotal Phase 2 BESTOW clinical trial for tegoprubart. The drug, aimed at preventing organ rejection in kidney transplant

New York, NY – November 10, 2025 – In a financial landscape often characterized by extremes, Cliff Asness, the influential co-founder of AQR Capital Management, offers a nuanced yet stark assessment of the current stock market: it is undeniably expensive, but crucially, it does not fit his stringent definition of a bubble.

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD) has successfully leveraged AI to design antibodies from scratch, achieving unprecedented atomic precision. This groundbreaking development, primarily driven by a sophisticated generative AI model [...]

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.

Cleveland-Cliffs shares gained 1.4% to close at $12.43 on Friday while Bristol-Myers Squibb shares gained 1% to close at $46.07.

Bristol Myers Squibb (BMY) offers strong value with a low P/E ratio, high profitability, and a robust 5.38% dividend yield, despite patent challenges.